Neil Littman

Neil Littman is a prominent figure in the biotechnology industry, with a strong background in healthcare investment banking and venture investing.

As the former CEO of ReIGNITE Therapeutics, Neil focused on developing advanced viral vector immunotherapies and gene therapies applying innovative technology.

His dedication to the field was sparked over a decade ago when he witnessed the cure of a young girl, Evie, from a genetic disease, which motivated his career trajectory.

Prior to his role at ReIGNITE Therapeutics, Neil was involved in managing significant funds at the California Institute for Regenerative Medicine, where he oversaw substantial investments in various clinical trials for diseases like cancer and neurodegenerative disorders.

Neil also held a key role at Notable Labs, a precision oncology company, where he excelled in business development and contributed to a successful Series B funding round.

His extensive experience in venture investing includes positions at Bioverge Ventures and Riverine Ventures, showcasing his diverse skill set and industry knowledge.

Neil's career began in healthcare investment banking on Wall Street, advising on transactions totaling over $1 billion, before transitioning to roles at notable biotech VC firms like Burrill & Company.

He holds a Master of Science in Biotechnology from The Johns Hopkins University and a B.A. in Molecular, Cellular, & Developmental Biology from the University of Colorado Boulder, highlighting his strong educational foundation in the life sciences.